Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Nov 30;13(11):6594-6597.
doi: 10.21037/tcr-24-952. Epub 2024 Nov 12.

The next frontier in breast cancer: genomic co-alteration and its impact on biology and treatment planning

Meredith Li  1 , Eitan Amir  1
Affiliations
Editorial

The next frontier in breast cancer: genomic co-alteration and its impact on biology and treatment planning

Meredith Li et al. Transl Cancer Res. .
No abstract available

Keywords: Breast cancer; genomics; precision medicine.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-952/coif). E.A. declares honoraria from Gilead, Novartis and Pfizer. The other author has no conflicts of interest to declare.

Comment on

References

    1. Lüönd F, Tiede S, Christofori G. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer 2021;125:164-75. 10.1038/s41416-021-01328-7 - DOI - PMC - PubMed
    1. Nickels S, Truong T, Hein R, et al. Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet 2013;9:e1003284. 10.1371/journal.pgen.1003284 - DOI - PMC - PubMed
    1. Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017;377:523-33. 10.1056/NEJMoa1706450 - DOI - PubMed
    1. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med 2021;384:2394-405. 10.1056/NEJMoa2105215 - DOI - PMC - PubMed
    1. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019;380:1929-40. 10.1056/NEJMoa1813904 - DOI - PubMed